Alendronate Once Weekly for the Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients (CFOS Trial)

BACKGROUND: Patients with cystic fibrosis (CF) are at risk for early bone loss, and demonstrate increased risks for vertebral fractures and kyphosis. A multicenter, randomized, controlled trial was conducted to assess the efficacy, tolerability, and safety of therapy with oral alendronate (FOSAMAX;...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Chest
Autores principales: Papaioannou, Alexandra, Kennedy, Courtney C., Freitag, Andreas, Ioannidis, George, O’Neill, John, Webber, Colin, Pui, Margaret, Berthiaume, Yves, Rabin, Harvey R., Paterson, Nigel, Jeanneret, Alphonse, Matouk, Elias, Villeneuve, Josee, Nixon, Madeline, Adachi, Jonathan D.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2008
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5104558/
https://ncbi.nlm.nih.gov/pubmed/18641106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1378/chest.08-0608
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares